Status:
COMPLETED
Livalo Acute Myocardial Infarction Study (LAMIS)
Lead Sponsor:
JW Pharmaceutical
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
Brief Summary
This study is performed to observe the incidence of major cardiovascular events in Korean patients with AMI after giving pitavastatin 2mg and 4mg longer than 1 year.
Eligibility Criteria
Inclusion
- Patients with STEMI, NSTEMI
- Patients satisfying at least one of the followings
- Patients with LDL-C ≥ 130 mg/dL
- Patients with LDL-C ≥ 100 mg/dL who are regarded as required cholesterol lowering therapy by the investigator
- Patients taking statin are required continuous cholesterol lowering therapy
- Patients satisfying at least two of the followings
- The change of Ischemic ECG
- CK, CK-MB, Troponin-I increased more than two times
- The symptom of ACS
Exclusion
- Patients with in-stent restenosis after PCI or coronary artery bypass
- Patients with cardiogenic shock
- Patients with severe heart failure (Left ventricular ejection fraction is less than 30%)
- Patients who are taking cyclosporine
- Patients who experienced hypersensitivity to pitavastatin
- Patients under dialysis treatment
- Patients who are participating other clinical trials
- Patients who can not stop taking concomitant drugs
- Pregnant or lactating women or suspected pregnancy
- Patients who are regarded as ineligible for this study by the investigator
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2014
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT01265706
Start Date
July 1 2010
End Date
December 1 2014
Last Update
December 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chonnam National University Hospital
Gwangju, South Korea